Aspen Neuroscience, Inc.

ASPE chart

Aspen Neuroscience, Inc. news

• ASPE SEC Filings - Aspen Neuroscience, Inc.

  Stock Titan · Oct 31, 9:34 PM EDT

• Aspen Neuroscience, Inc. SEC Filing (Oct 30, 2026)

  Stock Titan · Oct 31, 8:41 PM EDT

• Parkinson’s developer Aspen Neuroscience (ASPE) offers IPO shares with 15 patients dosed.

  Stock Titan · Oct 31, 8:41 PM EDT

• U.S. Stock Market Movements | Clinical-stage biotechnology company Aspen Neuroscience (ASPE.US) lists on U.S. exchanges, shares drop over 17% after opening

  Moomoo · Oct 30, 7:38 PM EDT

• Aspen Neuroscience IPO slips below $15

  Briefs Finance · Oct 30, 7:20 PM EDT

• Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO

  TradingView · Oct 30, 4:49 PM EDT

• Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

  Bloomberg · Oct 30, 4:09 PM EDT

• Gross margin % of ASPEN NEUROSCIENCE INC – NASDAQ:ASPE

  TradingView · Oct 30, 4:02 PM EDT

• Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO

  Latham & Watkins LLP · Oct 30, 3:17 PM EDT

• Debt to assets ratio of ASPEN NEUROSCIENCE INC – NASDAQ:ASPE

  TradingView · Oct 30, 3:17 PM EDT

• Bambusa Therapeutics and Aspen Neuroscience Shares Fall in Nasdaq Debuts

  TOKENPOST · Oct 30, 2:53 PM EDT

• Cash flow from operating activities of ASPEN NEUROSCIENCE INC – NASDAQ:ASPE

  TradingView · Oct 30, 1:54 PM EDT

Aspen Neuroscience, Inc. key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• S-1S-12026-10-09

About Aspen Neuroscience, Inc.

Ticker

ASPE (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

San Diego, CA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

2124080

Frequently asked questions